drugset / Trial / NCT00086203
Study of Talabostat and Rituximab in Advanced Chronic Lymphocytic Leukemia (CLL)
Non-randomizedSingle-groupOpen-labelTreatment
Summary
The objective of this study is to assess the efficacy and safety of talabostat and rituximab in patients with advanced CLL who failed to respond, or have progressed following a prior response, to a fludarabine regimen.
Timeline
- Start
- —
- Primary completion
- —
- Completion
- 2007-09
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Rituximab | Monoclonal antibody | — | — |
| Subject | talabostat | Small molecule | — | — |